AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21156931 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Channel Blocker (CCB)
Number of subjects: 5598
Study 21156931 — intervention group
Group type: COMPARATOR
Intervention: β-blocker (BB)
Number of subjects: 5598
Study 21156931 — intervention group
Group type: EXPERIMENTAL
Intervention: CACNB2 rs11014166
Number of subjects: 5598
Study 16814412 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-estradiol (1 mg)
Number of subjects: 22
Study 16814412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15591730 — intervention group
Group type: EXPERIMENTAL
Intervention: Information on tooth-brushing techniques
Number of subjects: 925
Study 15591730 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription of fluoride lozenges
Number of subjects: 925
Study 15591730 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-annual applications of fluoride varnish
Number of subjects: 925
Study 15591730 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly appointments with individualized information and fluoride varnish application
Number of subjects: 925
Study 15591730 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 925
Study 12405170 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation at a dose of 2 mg/kg/day
Number of subjects: 113
Study 12405170 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation at a dose of 2 mg/kg/every other day
Number of subjects: 113
Study 12405170 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation at a dose of 1 mg/kg/day
Number of subjects: 113
Study 12405170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 10519502 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% oxygen
Number of subjects: 30
Study 10519502 — intervention group
Group type: COMPARATOR
Intervention: 80% oxygen
Number of subjects: 30
Study 7745517 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic surfactant
Number of subjects: 344
Study 7745517 — intervention group
Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 344
Study 1981317 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 12
Study 1981317 — intervention group
Group type: EXPERIMENTAL
Intervention: Bopindolol
Number of subjects: 12
Study 6994301 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-morning daily prednisone treatment
Number of subjects: 0
Study 6994301 — intervention group
Group type: COMPARATOR
Intervention: Alternate-day prednisone treatment
Number of subjects: 0
Study 31174055 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 1500
Study 31174055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study 28490674 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid oil (22.25 g coconut oil or sunflower oil)
Number of subjects: 16
Study 28490674 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleogel (25 g coconut oleogel or sunflower oleogel)
Number of subjects: 16
Study 28490674 — intervention group
Group type: COMPARATOR
Intervention: Control (orange juice and rice porridge)
Number of subjects: 16
Study 25844709 — intervention group
Group type: EXPERIMENTAL
Intervention: Thickened amino acid-based formula (TAAF, Novalac)
Number of subjects: 75
Study 25844709 — intervention group
Group type: COMPARATOR
Intervention: Reference amino acid-based formula (RAAF, Neocate)
Number of subjects: 75
Study 23604006 — intervention group
Group type: EXPERIMENTAL
Intervention: Object alternation (OA)
Number of subjects: 3
Study 23604006 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed response (DR)
Number of subjects: 3
Study 23604006 — intervention group
Group type: COMPARATOR
Intervention: Delayed alternation (DA)
Number of subjects: 3
Study 22432725 — intervention group
Group type: EXPERIMENTAL
Intervention: Flax seed powder (10 g daily for 1 month)
Number of subjects: 29
Study 18778967 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging reminders
Number of subjects: 102
Study 18778967 — intervention group
Group type: COMPARATOR
Intervention: No text messaging activity (Control)
Number of subjects: 102
Study 17588299 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 120 mg once daily
Number of subjects: 339
Study 17588299 — intervention group
Group type: EXPERIMENTAL
Intervention: indomethacin 50 mg three times daily
Number of subjects: 339
Study 17588299 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib or indomethacin
Number of subjects: 339
Study 15450438 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous Communication (SC)
Number of subjects: 4
Study 15450438 — intervention group
Group type: COMPARATOR
Intervention: Speech Alone (SA)
Number of subjects: 4
Study 11451727 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread with 1.2 mg Zn and 17 microg folic acid (A)
Number of subjects: 15
Study 11451727 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread with 1.2 mg Zn and 144 microg folic acid (B)
Number of subjects: 15
Study 11451727 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread with 3.0 mg Zn and 17 microg folic acid (C)
Number of subjects: 15
Study 11451727 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread with 2.9 mg Zn and 144 microg folic acid (D)
Number of subjects: 15
Study 9727794 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal O2 plus CO2
Number of subjects: 9
Study 9727794 — intervention group
Group type: COMPARATOR
Intervention: Air applied by nasal prongs (control)
Number of subjects: 9
Study 7752830 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg
Number of subjects: 34
Study 7752830 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg plus CoQ10 100 mg
Number of subjects: 34
Study 3159346 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophyllan (SPG) combined with MF regimen (MMC + 5‐FU)
Number of subjects: 367
Study 3159346 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophyllan (SPG) combined with F regimen (Tegafur)
Number of subjects: 367
Study 29477372 — intervention group
Group type: EXPERIMENTAL
Intervention: MAPSS‐MS intervention (8-week duration)
Number of subjects: 183
Study 29477372 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus freely available computer games
Number of subjects: 183
Study 26415090 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnographic monitoring
Number of subjects: 242
Study 26415090 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring
Number of subjects: 242
Study 25041459 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking abstinence
Number of subjects: 427
Study 22574377 — intervention group
Group type: EXPERIMENTAL
Intervention: Yimusake 1 tablet (50 mg) per day for 4 weeks
Number of subjects: 68
Study 22574377 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone hydrochloride 1 tablet (50 mg) per day for 4 weeks
Number of subjects: 68
Study 20377924 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation
Number of subjects: 70
Study 17825113 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counselling on diet and physical activity during five routine visits to a public health nurse
Number of subjects: 92
Study 17825113 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 92
Study 17686104 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 expression in nasal epithelium
Number of subjects: 0
Study 17686104 — intervention group
Group type: COMPARATOR
Intervention: Steroid treatment or allergen provocation
Number of subjects: 0
Study 17686104 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IL-10 expression
Number of subjects: 0
Study 15844727 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills-based bibliotherapy approach (self-help book)
Number of subjects: 110
Study 15844727 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 110
Study 10868327 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral threshold ECT
Number of subjects: 28
Study 10868327 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral suprathreshold ECT
Number of subjects: 28
Study 10868327 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral threshold ECT
Number of subjects: 28
Study 10868327 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral suprathreshold ECT
Number of subjects: 28
Study 10868327 — intervention group
Group type: COMPARATOR
Intervention: Baseline RPP
Number of subjects: 28
Study 10868327 — intervention group
Group type: EXPERIMENTAL
Intervention: Ictal RPP
Number of subjects: 28
Study 10868327 — intervention group
Group type: EXPERIMENTAL
Intervention: Postictal RPP
Number of subjects: 28
Study 9013366 — intervention group
Group type: EXPERIMENTAL
Intervention: rHu GM‐CSF (5 micrograms/kg subcutaneously daily for 4 days)
Number of subjects: 8
Study 9013366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9013366 — intervention group
Group type: EXPERIMENTAL
Intervention: rHu GM‐CSF after the first dose
Number of subjects: 8
Study 9013366 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (200 mg orally every 8 hours)
Number of subjects: 8
Study 10183639 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS of unspecified origin
Number of subjects: 180
Study 10183639 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS in a hemophiliac infected by blood transfusion
Number of subjects: 180
Study 10183639 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukemia
Number of subjects: 180
Study 10183639 — intervention group
Group type: EXPERIMENTAL
Intervention: Both categories of AIDS patients
Number of subjects: 180
Study 10183639 — intervention group
Group type: COMPARATOR
Intervention: All three diagnostic categories
Number of subjects: 180
Study 10183639 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigay bias
Number of subjects: 180
Study 2859713 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 18
Study 2859713 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine
Number of subjects: 18
Study 30870744 — intervention group
Group type: EXPERIMENTAL
Intervention: Humorous parody images of thin-ideal celebrity posts
Number of subjects: 102
Study 30870744 — intervention group
Group type: COMPARATOR
Intervention: Thin-ideal celebrity images
Number of subjects: 102
Study 28235506 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% mepivacaine with normal dilution (ND group, 35 patients)
Number of subjects: 70
Study 28235506 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% mepivacaine with 5% dextrose dilution (D5 group, 35 patients)
Number of subjects: 70
Study 28235506 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% mepivacaine with normal dilution (ND group)
Number of subjects: 70
Study 28235506 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% mepivacaine with 5% dextrose dilution (D5 group)
Number of subjects: 70
Study 26238672 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 200 mg
Number of subjects: 1598
Study 26238672 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 400 mg
Number of subjects: 1598
Study 26238672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1598
Study 24420340 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-onset Pompe disease patients
Number of subjects: 10
Study 23923597 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention (10 sessions: 3 individual, 5 with family, 2 small group)
Number of subjects: 60
Study 23923597 — intervention group
Group type: COMPARATOR
Intervention: Routine drug treatment (control group)
Number of subjects: 60
Study 19389561 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 3565
Study 17464552 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration supplementation (1500 ml of water + 1500 mg of NaCl/day)
Number of subjects: 86
Study 17464552 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 86
Study 15547181 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel-carboplatin
Number of subjects: 1077
Study 15547181 — intervention group
Group type: COMPARATOR
Intervention: paclitaxel-carboplatin
Number of subjects: 1077
Study 11673814 — intervention group
Group type: EXPERIMENTAL
Intervention: HGC‐SQV‐based HAART (Arm A)
Number of subjects: 262
Study 11673814 — intervention group
Group type: EXPERIMENTAL
Intervention: IDV‐based HAART (Arm B)
Number of subjects: 262
Study 11673814 — intervention group
Group type: COMPARATOR
Intervention: Both arms (Arm A and Arm B)
Number of subjects: 262
Study 9271010 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneuploid mAgNOR counts of >= 2.4 in cases associated with malignancy (80% of 16 cases)
Number of subjects: 69
Study 9271010 — intervention group
Group type: COMPARATOR
Intervention: Aneuploid mAgNOR counts of >= 2.4 in cases not associated with malignancy (11% of 53 cases)
Number of subjects: 69
Study 9271010 — intervention group
Group type: EXPERIMENTAL
Intervention: pAgNOR counts
Number of subjects: 69
Study 7909999 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical levocabastine (eye drops and nasal spray)
Number of subjects: 27
Study 7909999 — intervention group
Group type: COMPARATOR
Intervention: Oral terfenadine
Number of subjects: 27
Study 3299678 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (10 mg intravenously twice daily) + Neostigmine (0.5 mg subcutaneously twice daily)
Number of subjects: 51
Study 3299678 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (0.5 mg subcutaneously twice daily)
Number of subjects: 51
Study 3299678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 29419920 — intervention group
Group type: EXPERIMENTAL
Intervention: V0034CR emollient
Number of subjects: 335
Study 29419920 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference emollient
Number of subjects: 335
Study 29419920 — intervention group
Group type: COMPARATOR
Intervention: No emollient
Number of subjects: 335
Study 27412490 — intervention group
Group type: EXPERIMENTAL
Intervention: Colored indicator gloves
Number of subjects: 574
Study 27412490 — intervention group
Group type: COMPARATOR
Intervention: Standard gloves
Number of subjects: 574
Study 24738073 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Number of subjects: 81
Study 24738073 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Exercise (MICE)
Number of subjects: 81
Study 24738073 — intervention group
Group type: COMPARATOR
Intervention: Sedentary Control
Number of subjects: 81
Study 23778903 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 14264
Study 23778903 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14264
Study 20843456 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercises (16 sessions, twice a week for 30 minutes)
Number of subjects: 50
Study 18164521 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive AIDS vaccine
Number of subjects: 50000000
Study 16507186 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 16
Study 16507186 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 16
Study 16507186 — intervention group
Group type: COMPARATOR
Intervention: Control (systolic blood pressure > 90 mmHg)
Number of subjects: 16
Study 12222975 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE) to guide electrical cardioversion
Number of subjects: 0
Study 12222975 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (cardioversion following 3 weeks of anticoagulation)
Number of subjects: 0
Study 10590282 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg twice daily
Number of subjects: 499
Study 10590282 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin 1 g iv three-times daily
Number of subjects: 499
Study 7797060 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study 7797060 — intervention group
Group type: COMPARATOR
Intervention: Inhaled beta 2-agonists
Number of subjects: 0
Study 2194992 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (150 mg/day)
Number of subjects: 0
Study 2194992 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitrypylinoxide (150 mg/day)
Number of subjects: 0
Study 115367 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29572676 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 µg/day of vitamin D3
Number of subjects: 119
Study 29572676 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 µg/day of vitamin D3
Number of subjects: 119
Study 29572676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 27891629 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 70
Study 27891629 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide (CH)
Number of subjects: 70
Study 27891629 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MTA and CH
Number of subjects: 70
Study 25820474 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1.3 g/day
Number of subjects: 73
Study 25820474 — intervention group
Group type: EXPERIMENTAL
Intervention: α-lipoic acid 0.3 g/day
Number of subjects: 73
Study 25820474 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EPA (1.3 g/day) and α-lipoic acid (0.3 g/day)
Number of subjects: 73
Study 25820474 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 73
Study 24059443 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Metronome (IM) therapy
Number of subjects: 46
Study 24059443 — intervention group
Group type: COMPARATOR
Intervention: Standard Rehabilitation Care (SRC)
Number of subjects: 46
Study 21126869 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care intervention
Number of subjects: 464
Study 21126869 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 464
Study 21126869 — intervention group
Group type: EXPERIMENTAL
Intervention: QUAL-EC
Number of subjects: 464
Study 19576804 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with NaviTip FX
Number of subjects: 40
Study 19576804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent passive ultrasonic irrigation (PUI)
Number of subjects: 40
Study 19576804 — intervention group
Group type: COMPARATOR
Intervention: No activation (control)
Number of subjects: 40
Study 19576804 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous PUI with irrigant delivered at pulp chamber
Number of subjects: 40
Study 19576804 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous PUI with irrigant delivered through the ultrasonic unit
Number of subjects: 40
Study 16832589 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation (REH) - pelvic floor muscle training and behavioral training over 5 visits in 3 months
Number of subjects: 44
Study 16832589 — intervention group
Group type: COMPARATOR
Intervention: Medication (MED) - extended release oxybutynin at 5 mg/day for 3 months
Number of subjects: 44
Study 15516392 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin bolus dose
Number of subjects: 40
Study 15516392 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Number of subjects: 40
Study 11353937 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical force, manually assisted (MFMA) manipulation
Number of subjects: 30
Study 11353937 — intervention group
Group type: COMPARATOR
Intervention: Specific contact high-velocity, low-amplitude (HVLA) manipulation
Number of subjects: 30
Study 9024436 — intervention group
Group type: EXPERIMENTAL
Intervention: Debridement
Number of subjects: 0
Study 9024436 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair
Number of subjects: 0
Study 7934681 — intervention group
Group type: EXPERIMENTAL
Intervention: Head down position without PEEP
Number of subjects: 60
Study 7934681 — intervention group
Group type: EXPERIMENTAL
Intervention: Head down position with PEEP 5 cmH2O
Number of subjects: 60
Study 7934681 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithotomy position without PEEP
Number of subjects: 60
Study 7934681 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithotomy position with PEEP 5 cmH2O
Number of subjects: 60
Study 7934681 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position without PEEP
Number of subjects: 60
Study 7934681 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position with PEEP 5 cmH2O
Number of subjects: 60
Study 3510764 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 81
Study 3510764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 31551154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine enrichment of culture medium (granulocyte‐macrophage colony‐stimulating factor, heparin‐binding epidermal growth factor‐like growth factor, and leukemia inhibitory factor)
Number of subjects: 443
Study 31551154 — intervention group
Group type: COMPARATOR
Intervention: No cytokines (control)
Number of subjects: 443
Study 31551154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine enrichment of culture medium
Number of subjects: 443
Study 28669793 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% methylene blue mediated photodynamic therapy using Fotosan device for 30s (630nm wavelength and 7.2‐14.4J/cm2 dose) for 4 sessions
Number of subjects: 30
Study 28669793 — intervention group
Group type: COMPARATOR
Intervention: 0.5mg tab dexamethasone solution in 5cc water, rinsed 4 times a day for two weeks
Number of subjects: 30
Study 26134837 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored, practice-based intervention delivered by bilingual medical assistants trained as Health Coaches
Number of subjects: 148
Study 26134837 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard hypertension treatment recommendations)
Number of subjects: 148
Study 26134837 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored, practice-based intervention
Number of subjects: 148
Study 23786760 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 2 × 25 mg s.c./week
Number of subjects: 26
Study 21321333 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta-burst stimulation (iTBS)
Number of subjects: 26
Study 21321333 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 26